Platinum-based chemotherapy is the standard regimen for the treatment of gynecologic cancers ; however, hypersensitivity reactions (HR) to platinum often lead to discontinuation of this effective treatment. Here we performed a desensitization protocol for platinum infusion in 3 patients who required platinum re-administration after developing HR. Two patients (Case 1 and 2) were treated with the desensitization protocol successfully without developing HR during the subsequent 3 courses. Case 3 tolerated desensitization well for 2 courses, but in the 3rd course, she developed severe HR immediately after the initiation of cisplatin infusion because the desensitization protocol was unintentionally omitted. These cases show the usefulness and e...
Objective: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a...
Background: Carboplatin based regimens have demonstrated activity in pediatric patients with low gra...
Context A recent meta-analysis suggests that the addition of oxaliplatin or cisplatin to gemcitabine...
Objectives: This aim of this study was to investigate the feasibility of re-treating patients who h...
Objective The purpose of this study was to evaluate the results of substituting cisplatin for carbo...
Aim: Hypersensitivity reactions to carboplatin are not an infrequent adverse event in ovarian cancer...
The treatment of ovarian cancer based on platinum analogs has taken on a new and additional importan...
Cisplatin was the first of the platinum drugs. Second-generation platinum derivative was carboplati...
Background. Allergic reactions to cisplatin are not uncommon situations with an incidence of 5-20%. ...
Background: Desensitization has been used for some decades to treat patients with the allergenic dru...
BACKGROUND AND OBJECTIVE: Desensitization protocols for patients with immediate hypersensitivity rea...
The relatively rapid development of a platinum-associated hypersensitivity reaction in an ovarian ca...
We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplati...
Abstract Hypersensitivity reaction to cisplatin can result in discontinuation of chemoradiotherapy i...
Abstract Carboplatin administration can usually be safely continued via a so-called desensitisation ...
Objective: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a...
Background: Carboplatin based regimens have demonstrated activity in pediatric patients with low gra...
Context A recent meta-analysis suggests that the addition of oxaliplatin or cisplatin to gemcitabine...
Objectives: This aim of this study was to investigate the feasibility of re-treating patients who h...
Objective The purpose of this study was to evaluate the results of substituting cisplatin for carbo...
Aim: Hypersensitivity reactions to carboplatin are not an infrequent adverse event in ovarian cancer...
The treatment of ovarian cancer based on platinum analogs has taken on a new and additional importan...
Cisplatin was the first of the platinum drugs. Second-generation platinum derivative was carboplati...
Background. Allergic reactions to cisplatin are not uncommon situations with an incidence of 5-20%. ...
Background: Desensitization has been used for some decades to treat patients with the allergenic dru...
BACKGROUND AND OBJECTIVE: Desensitization protocols for patients with immediate hypersensitivity rea...
The relatively rapid development of a platinum-associated hypersensitivity reaction in an ovarian ca...
We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplati...
Abstract Hypersensitivity reaction to cisplatin can result in discontinuation of chemoradiotherapy i...
Abstract Carboplatin administration can usually be safely continued via a so-called desensitisation ...
Objective: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a...
Background: Carboplatin based regimens have demonstrated activity in pediatric patients with low gra...
Context A recent meta-analysis suggests that the addition of oxaliplatin or cisplatin to gemcitabine...